Louis H. Morrone

Insider · Executive Vice President · ABT

Louis H. Morrone files insider transactions with the SEC as an executive vice president of Abbott Laboratories (ABT). We hold 2 disclosed purchases and sales filed since 6 July 2021, 1 of them in the last 90 days.

Files forABT
Disclosed buys and sells2 in all, 1 in the last 90 days
Last disclosure13 August 2026

Positions held

1 post we hold — a term names its own dates; a run of filings only says when they filed

Filed 1 July 2021 — 12 August 2026Executive Vice President · Abbott Laboratories (ABT)46 Form 4 lines · source: SEC Form 4

Everything they disclosed

46 entries, newest first — one per disclosure report, one per Form 4 line

▼ sold on the open market 5,850 shares of Abbott LaboratoriesSEC Form 413 August 2026Common shares without par value · traded 11 August 2026 · filed 13 August 2026
recorded a discretionary transaction in 12 shares of Abbott LaboratoriesSEC Form 413 August 2026Common shares without par value · traded 12 August 2026 · filed 13 August 2026
had shares withheld for tax on 269 shares of Abbott LaboratoriesSEC Form 41 July 2026Common shares without par value · traded 30 June 2026 · filed 1 July 2026
had shares withheld for tax on 4,040 shares of Abbott LaboratoriesSEC Form 43 March 2026Common shares without par value · traded 27 February 2026 · filed 3 March 2026
▼ sold on the open market 1,144 shares of Abbott LaboratoriesSEC Form 43 March 2026Common shares without par value · traded 2 March 2026 · filed 3 March 2026
had shares withheld for tax on 4,040 shares of Abbott LaboratoriesSEC Form 43 March 2026Common shares without par value · traded 27 February 2026 · filed 3 March 2026
▼ sold on the open market 1,144 shares of Abbott LaboratoriesSEC Form 43 March 2026Common shares without par value · traded 2 March 2026 · filed 3 March 2026
was granted 15,418 shares of Abbott LaboratoriesSEC Form 426 February 2026Common shares without par value · traded 24 February 2026 · filed 26 February 2026
was granted 63,561 shares of Abbott Laboratories (a derivative holding)SEC Form 426 February 2026Option (right to buy) · traded 24 February 2026 · filed 26 February 2026
was granted 63,561 shares of Abbott Laboratories (a derivative holding)SEC Form 426 February 2026Option (right to buy) · traded 24 February 2026 · filed 26 February 2026
was granted 15,418 shares of Abbott LaboratoriesSEC Form 426 February 2026Common shares without par value · traded 24 February 2026 · filed 26 February 2026
had shares withheld for tax on 269 shares of Abbott LaboratoriesSEC Form 41 July 2025Common shares without par value · traded 30 June 2025 · filed 1 July 2025
had shares withheld for tax on 4,386 shares of Abbott LaboratoriesSEC Form 44 March 2025Common shares without par value · traded 28 February 2025 · filed 4 March 2025
▼ sold on the open market 1,111 shares of Abbott LaboratoriesSEC Form 44 March 2025Common shares without par value · traded 3 March 2025 · filed 4 March 2025
was granted 38,108 shares of Abbott Laboratories (a derivative holding)SEC Form 427 February 2025Option (right to buy) · traded 25 February 2025 · filed 27 February 2025
was granted 10,232 shares of Abbott LaboratoriesSEC Form 427 February 2025Common shares without par value · traded 25 February 2025 · filed 27 February 2025
▼ sold on the open market 2,644 shares of Abbott LaboratoriesSEC Form 430 January 2025Common shares without par value · traded 28 January 2025 · filed 30 January 2025
had shares withheld for tax on 269 shares of Abbott LaboratoriesSEC Form 42 July 2024Common shares without par value · traded 30 June 2024 · filed 2 July 2024
had shares withheld for tax on 556 shares of Abbott LaboratoriesSEC Form 42 July 2024Common shares without par value · traded 1 July 2024 · filed 2 July 2024
had shares withheld for tax on 3,455 shares of Abbott LaboratoriesSEC Form 44 March 2024Common shares without par value · traded 29 February 2024 · filed 4 March 2024
▼ sold on the open market 801 shares of Abbott LaboratoriesSEC Form 44 March 2024Common shares without par value · traded 1 March 2024 · filed 4 March 2024
was granted 46,257 shares of Abbott Laboratories (a derivative holding)SEC Form 423 February 2024Option (right to buy) · traded 21 February 2024 · filed 23 February 2024
was granted 12,309 shares of Abbott LaboratoriesSEC Form 423 February 2024Common shares without par value · traded 21 February 2024 · filed 23 February 2024
was granted 7,100 shares of Abbott Laboratories (a derivative holding)SEC Form 45 July 2023Option (right to buy) · traded 30 June 2023 · filed 5 July 2023
was granted 1,815 shares of Abbott LaboratoriesSEC Form 45 July 2023Common shares without par value · traded 30 June 2023 · filed 5 July 2023
had shares withheld for tax on 556 shares of Abbott LaboratoriesSEC Form 45 July 2023Common shares without par value · traded 1 July 2023 · filed 5 July 2023
had shares withheld for tax on 2,534 shares of Abbott LaboratoriesSEC Form 42 March 2023Common shares without par value · traded 28 February 2023 · filed 2 March 2023
▼ sold on the open market 1,092 shares of Abbott LaboratoriesSEC Form 42 March 2023Common shares without par value · traded 1 March 2022 · filed 2 March 2023
was granted 41,648 shares of Abbott Laboratories (a derivative holding)SEC Form 422 February 2023Option (right to buy) · traded 17 February 2023 · filed 22 February 2023
was granted 10,560 shares of Abbott LaboratoriesSEC Form 422 February 2023Common shares without par value · traded 17 February 2023 · filed 22 February 2023
had shares withheld for tax on 556 shares of Abbott LaboratoriesSEC Form 41 July 2022Common shares without par value · traded 1 July 2022 · filed 1 July 2022
had shares withheld for tax on 1,942 shares of Abbott LaboratoriesSEC Form 42 March 2022Common shares without par value · traded 28 February 2022 · filed 2 March 2022
▼ sold on the open market 656 shares of Abbott LaboratoriesSEC Form 42 March 2022Common shares without par value · traded 1 March 2022 · filed 2 March 2022
was granted 54,280 shares of Abbott Laboratories (a derivative holding)SEC Form 423 February 2022Option (right to buy) · traded 18 February 2022 · filed 23 February 2022
was granted 11,647 shares of Abbott LaboratoriesSEC Form 423 February 2022Common shares without par value · traded 18 February 2022 · filed 23 February 2022
exercised options over 9,988 shares of Abbott Laboratories (a derivative holding)SEC Form 421 December 2021Option (right to buy) · traded 17 December 2021 · filed 21 December 2021
exercised options over 9,988 shares of Abbott LaboratoriesSEC Form 421 December 2021Common shares without par value · traded 17 December 2021 · filed 21 December 2021
▼ sold on the open market 9,988 shares of Abbott LaboratoriesSEC Form 421 December 2021Common shares without par value · traded 17 December 2021 · filed 21 December 2021
exercised options over 9,989 shares of Abbott Laboratories (a derivative holding)SEC Form 48 December 2021Option (right to buy) · traded 6 December 2021 · filed 8 December 2021
exercised options over 9,988 shares of Abbott Laboratories (a derivative holding)SEC Form 48 December 2021Option (right to buy) · traded 7 December 2021 · filed 8 December 2021
exercised options over 9,989 shares of Abbott LaboratoriesSEC Form 48 December 2021Common shares without par value · traded 6 December 2021 · filed 8 December 2021
▼ sold on the open market 9,989 shares of Abbott LaboratoriesSEC Form 48 December 2021Common shares without par value · traded 6 December 2021 · filed 8 December 2021
exercised options over 9,988 shares of Abbott LaboratoriesSEC Form 48 December 2021Common shares without par value · traded 7 December 2021 · filed 8 December 2021
▼ sold on the open market 9,988 shares of Abbott LaboratoriesSEC Form 48 December 2021Common shares without par value · traded 7 December 2021 · filed 8 December 2021
was granted 19,291 shares of Abbott Laboratories (a derivative holding)SEC Form 46 July 2021Option (right to buy) · traded 1 July 2021 · filed 6 July 2021
was granted 3,764 shares of Abbott LaboratoriesSEC Form 46 July 2021Common shares without par value · traded 1 July 2021 · filed 6 July 2021

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.